Warner Chilcott and Sanofi-Aventis have amended their Actonel global collaboration agreement regarding the U.S. and Puerto Rico. Warner Chilcott will take full operational control for the promotion, marketing and R&D decisions for Actonel in the U.S. and PR, and will assume responsibility for all related costs. Warner Chilcott previously shared these costs with SA in these territories. In return, SA will receive collaboration payments based on U.S. and PR sales for the remainder of the collaboration agreement, which is set to expire at the end of 2014.

“The amendment to the collaboration agreement will enable Warner Chilcott to assume full control over the promotion and marketing of the Actonel brand in the U.S.,” stated Roger Boissonneault, president and chief executive officer of Warner Chilcott.”This will allow us improved flexibility to adjust our promotional plans in the U.S. as we prepare for the potential launch of the next generation Actonel product.”